Su Ting-Yi, Ye Jung-Jr, Hsu Po-Chang, Wu Hsuan-Feng, Chia Ju-Hsin, Lee Ming-Hsun
Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Department of Laboratory Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan, Taiwan.
J Microbiol Immunol Infect. 2015 Apr;48(2):175-82. doi: 10.1016/j.jmii.2013.07.009. Epub 2013 Sep 21.
To identify the clinical characteristics and risk factors for mortality of patients with cefepime-resistant Pseudomonas aeruginosa (FRPa) bacteremia.
This retrospective study analyzed adult patients with FRPa bacteremia hospitalized between January 2006 and December 2011.
Seventy eight patients (46 male, 32 female; mean age: 72.2 ± 14.1 years) were included. Of them, 46 (59.0%) had ventilator use and 45 (57.7%) had intensive care unit stay. All the bacteremia episodes were health-care associated or hospital acquired, and 55.1% of FRPa blood isolates were multidrug resistant. The sources of bacteremia were identified in 42 patients (53.8%), with pneumonia being the most common one (28/42; 66.7%). The mean interval between admission and the sample date of the first FRPa-positive blood culture was 45.8 ± 52.6 days. The mean Pittsburgh bacteremia score was 5.0 ± 3.4. The 15-day and 30-day mortality rates were 50.0% and 65.4%, respectively. Patients (41; 52.6%) on appropriate antibiotic therapy within 72 hours of the first FRPa-positive blood culture had a higher 30-day survival rate than those without (48.8% vs. 18.9%, p = 0.011 by log-rank test). Multivariate analyses revealed that a higher Pittsburgh bacteremia score was an independent risk factor for either 15-day (p = 0.002) or 30-day mortality (p = 0.010), and appropriate antibiotic therapy within 72 hours was an independent protecting factor for either 15-day (p = 0.049) or 30-day mortality (p = 0.017).
FRPa bacteremia had a high mortality rate. The disease severity and appropriate antimicrobial therapy within 72 hours of positive blood culture were related to the patients' outcome.
确定耐头孢吡肟铜绿假单胞菌(FRPa)菌血症患者的临床特征及死亡危险因素。
这项回顾性研究分析了2006年1月至2011年12月期间住院的成年FRPa菌血症患者。
纳入78例患者(男性46例,女性32例;平均年龄:72.2±14.1岁)。其中,46例(59.0%)使用了呼吸机,45例(57.7%)入住了重症监护病房。所有菌血症发作均与医疗保健相关或为医院获得性,55.1%的FRPa血培养分离株对多种药物耐药。42例患者(53.8%)确定了菌血症来源,其中肺炎最为常见(28/42;66.7%)。首次FRPa阳性血培养的入院日期与采样日期之间的平均间隔为45.8±52.6天。匹兹堡菌血症评分平均为5.0±3.4。15天和30天死亡率分别为50.0%和65.4%。在首次FRPa阳性血培养72小时内接受适当抗生素治疗的患者(41例;52.6%)30天生存率高于未接受治疗的患者(48.8%对18.9%,对数秩检验p=0.011)。多因素分析显示,较高的匹兹堡菌血症评分是15天(p=0.002)或30天死亡率(p=0.010)的独立危险因素,72小时内适当的抗生素治疗是15天(p=0.049)或30天死亡率(p=0.017)的独立保护因素。
FRPa菌血症死亡率高。疾病严重程度及血培养阳性72小时内适当的抗菌治疗与患者预后相关。